Feature | December 17, 2014

Philips Acquires Volcano for $1 Billion to Expand Position in Interventional Lab Market

Volcano offers catheter-based intravascular ultrasound imaging and FFR measurement solutions for cardiovascular applications

Volcano, Philips, acquisition, FFR, IVUS

Volcano's IVUS system with virtual histology, which shows a color code for the hardness of materials that make up coronary artery plaque.

December 17, 2014 — Philips Healthcare and Volcano Corp. entered into a definitive merger agreement, where Philips will purchase shares of Volcano for a total price of about $1 billion.

The purchase will enable Philips to further expand its advanced imaging capabilities of its angiography suite. Volcano is a leader in intravascular ultrasound (IVUS) and fractional flow reserve (FFR) catheter measurements used in the interventional cardiology cath lab. The additional technology will enhance Philips' angiography imaging system suite offerings.

The board of directors of Volcano has unanimously approved the transaction and recommends the offer to its shareholders. The transaction is expected to close in the first quarter of 2015. 

In the last few years, Philips has created a leading image-guided therapy business through strategic investments in R&D, partnerships and technology licenses. Today, Philips has a rich portfolio of interventional imaging equipment, navigation tools and services, and a sizeable global customer base, including each of the top 50 U.S. heart surgery and cardiology hospitals. One in three interventional X-ray systems sold globally is a Philips system. These systems provide the visual maps that allow the clinician to guide catheters through the body to perform the minimally invasive treatment.

"In a rather bold move, Philips is hedging their bets that the future of cardiovascular treatments will see a higher use of image guidance in interventional procedures,” said Frost & Sullivan Advanced Medical Technologies Research Analyst Tara Shelton. “These minimally-invasive procedures improve patient recovery time and reduce radiation exposure, among other positive impacts on clinical, operational and financial outcomes, making them extremely well aligned with the current priorities of the U.S. as well as many other healthcare systems. IVUS is predominately used in the Japan healthcare market with it being used in nearly 80 percent of cardiovascular cases compared to the U.S. where it is used about 10 percent of the time.”

With 2013 sales of approximately $400 million, San Diego, California-based Volcano is a leader in catheter–based imaging and measurements for minimally invasive diagnostics and treatment of coronary artery disease and peripheral vascular disease. Volcano is the only company in the industry with a leading position in both IVUS imaging and FFR measurements. In addition, the company possesses the broadest product portfolio around these two technologies, a leading IP position and a nascent peripheral vascular therapeutics business that targets a segment with a double-digit growth rate.

The combination of two industry leaders will create new sources of recurring revenue streams and increase sales growth for Philips in the EUR 4 billion image-guided therapy market opportunity. Sales growth will be accelerated through Volcano’s close customer relationships associated with its disposable products and channel synergies that will create cross-selling opportunities between both companies’ existing customer bases. Furthermore, the combination of Volcano’s proven clinical development and commercialization capabilities with Philips’ next generation of imaging and measurement technologies, will allow Philips to introduce new solutions in higher growth segments such as the minimally invasive treatment of heart rhythm disorders and structural heart diseases. These are promising segments growing at double-digit rates.

“The agreement to acquire Volcano significantly advances our strategy to become the leading systems integrator in image-guided therapies,” said Frans van Houten, Philips CEO. ”Volcano’s impressive and unique product portfolio is highly complementary to our strong offering in live image-guidance solutions, creating an opportunity to accelerate the revenue growth for our image-guided therapy business to a high single-digit rate by 2017. Our combined sales forces will be able to capture immediate cross selling opportunities, while our joint R&D teams will be able to develop new solutions to address significant unmet needs in the minimally invasive treatment of cardiovascular diseases.”

“Image-guided therapies provide significant benefits for healthcare systems and patients, including reduced patient trauma, shorter recovery times and hospital stays, and lower costs,” Mr. Van Houten added. “As a result, our clinical partners and customers are asking for a tighter integration of imaging and measurement technologies to enable such therapies. This transaction allows us to provide our customers with an integrated solution to improve procedural outcomes at a decisive stage in the health continuum.” 

“I am very excited that Volcano will become part of Philips and join forces with its leading image guided therapy business,” said Scott Huennekens, Volcano president and CEO. “This transaction will be beneficial for our shareholders, customers, partners and employees. There is a large and growing global market opportunity for image-guided therapies, and as part of Philips, we gain the scale and resources needed to accelerate our goals of improving patient outcomes on a global basis, lowering cost and delivering innovative diagnostics and therapies in the coronary and peripheral markets. In addition, our shared expertise in the image-guided therapy market will allow us to further globalize our leading IVUS and FFR product offerings and enter new product areas.  We look forward to working closely with Philips and ensuring a smooth transition and closing.”

Upon completion of the transaction, the Volcano business and its 1,800 employees will be part of a dedicated, new image-guided therapy business group within Philips, which will be led by Philips executive Bert van Meurs, an experienced leader in the health care industry with a proven track record in the image-guided therapy market.

“While there is clearly a premium involved for Volcano shareholders, this acquisition occurs amidst a major reorganization of Philips,” said Frost & Sullivan Advanced Medical Technologies Principal Analyst Nadim Daher. ??"As the medical imaging company amongst the ‘big three’ that is the most strategically focused on the cardiology segment of the market, Philips is continuing on the recent strides it has been making with regard to the integration of multiple imaging modalities in the cath lab. While other industry efforts, led mostly by Philips, are putting diagnostic ultrasound to better use in the interventional cardiology suite, the acquisition of Volcano promises a similar expansion of IVUS. At the same time, the acquisition creates a new competitive landscape in the IVUS market and a new competitive front for Philips.”  
 
Financials

The acquisition will create a strategically and financially compelling combination that will provide higher growth, additional operating leverage through more productive sales operations, and enhance commercialization opportunities in new, adjacent segments. Philips will drive operational performance improvements through cost synergies and the implementation of proven productivity improvement methodologies such as Lean.  As a result, the transaction is expected to be accretive to Philips’ reported earnings per share by 2017, and Philips targets an EBITA margin for its image-guided therapy business group of around 20% by 2017.

The transaction is structured as a cash tender offer by Philips for all of the issued and outstanding shares of Volcano, to be followed by a merger in which each share of Volcano not tendered in the tender offer will be converted into the USD 18.00 per share price paid in the tender offer. Pursuant to the merger agreement, the transaction is subject to customary closing conditions, including certain regulatory clearances in the U.S. and in certain non-U.S. jurisdictions. The tender offer is not subject to any financing conditions. Philips intends to finance the acquisition through a combination of cash on hand and the issuance of debt.

For more information: www.volcanocorp.com

 

Related Content

Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Siemens Healthineers Announces First U.S. Install of Artis Pheno Angiography System
News | Angiography | July 05, 2017
July 5, 2017 — Michigan Medicine recently became the first healthcare institution in the United States to install the
RaySafe Introduces Pro-Slit Camera for Accurate Focal Spot Measurement
Technology | Digital Radiography (DR) | June 27, 2017
Unfors RaySafe recently introduced the RaySafe Pro-Slit Phantom and the RaySafe Pro-Stand.
New Hampshire Hospital Expands Vascular Care with Toshiba Medical's Infinix-i Sky +
News | Angiography | April 27, 2017
Wentworth-Douglass Hospital in Dover, N.H., installed Toshiba Medical’s Infinix-i Sky + angiography system in its...
Louisiana Medical Center Installs First U.S. Toshiba Medical Infinix-i Sky +
News | Angiography | April 18, 2017
Patients at Terrebonne General Medical Center (TGMC) in Houma, La., now have access to safe, high-quality...
Siemens Healthineers, ACC 2017, syngo CTO Guidance, Compressed Sensing Cardiac Cine
News | Cardiac Imaging | March 16, 2017
During the 66th Annual Scientific Session & Expo of the American College of Cardiology (ACC), March 17-19 in...
Siemens Healthineers, Artis pheno angiography system, FDA approval, ACC 2017, RSNA 2017
Technology | Angiography | March 15, 2017
The U.S. Food and Drug Administration (FDA) has cleared the Artis pheno robotic C-arm angiography system from Siemens...
Technical University of Munich, Munich Compact Light Source, MuCLS, angiography, contrast agents

(a) Photograph of the sample in waterbath. (b) Empty image of full MuCLS beam. (c) Quasi-mono-energetic angiography image of a porcine heart acquired at the MuCLS, with iodine-based contrast agent injected into the left coronary artery. Visible are the left anterior descending artery (LAD) and the left circumflex artery (LCX). Image courtesy of the authors.

News | Angiography | March 10, 2017
The most prevalent method for obtaining images of clogged coronary vessels is coronary angiography. For some patients,...
ON Semiconductor, KAF-09001 image sensor, video imaging, digital radiography, angiography, radiographic fluoroscopy, R/F systems
Technology | Radiographic Fluoroscopy (RF) | March 06, 2017
ON Semiconductor announced the release of a new CCD image sensor that enables video imaging under reduced X-ray dosage...
Philips, Azurion platform, angiography, interventional lab, global launch
Technology | Hybrid OR | March 03, 2017
Philips recently announced the global launch of Azurion, its next-generation image-guided therapy platform.
Overlay Init